Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Evofosfamide · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Castration-resistant prostate cancer | EXPERIMENTAL | Evofosfamide + zalifrelimab + balstilimab |
| Pancreatic cancer | EXPERIMENTAL | Evofosfamide + zalifrelimab + balstilimab |
| Human papilloma virus-negative squamous cell carcinoma of the head and neck | EXPERIMENTAL | Evofosfamide + zalifrelimab + balstilimab |
| Name | Type | Description |
|---|---|---|
| Evofosfamide | DRUG | Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3. |
| Zalifrelimab | DRUG | Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5. |
| Balstilimab | DRUG | Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1. |
Inclusion Criteria: 1. Histologically confirmed locally advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, or HPV-negative SCCHN for which no other lines of standard therapy with demonstrated clinical benefit are available or appropriate as treatment. 2. Appropriate to ...
Top 20 of 53 competitors
Evofosfamide is an investigational small molecule being studied for the treatment of metastatic prostate cancer. It is also being evaluated in metastatic head and neck squamous cell carcinoma and metastatic pancreatic cancer. The drug is currently in Phase 1 clinical development.
Evofosfamide is being developed by Agenus Inc., a biopharmaceutical company. Agenus is listed on the stock exchange under the ticker symbol AGEN. The company is conducting clinical trials to evaluate the safety and efficacy of Evofosfamide in various cancer indications.
Evofosfamide is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to study the drug in combination with other agents for the treatment of certain metastatic cancers.
Evofosfamide is being studied in a Phase 1 clinical trial with the identifier NCT06782555. This trial is evaluating Evofosfamide in combination with Zalifrelimab and Balstilimab in patients with metastatic prostate cancer, metastatic head and neck squamous cell carcinoma, and metastatic pancreatic cancer. The trial is currently recruiting participants in the United States.
The specific molecular target of Evofosfamide is not disclosed in the available information. As a small molecule, it is being investigated for its potential anti-cancer activity. The ongoing clinical trial is studying its effects in combination with other therapies, but the exact mechanism of action has not been detailed.